Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Kite Pharma's IPO nets $118.6mm

Executive Summary

Kite Pharma Inc. (autologous cell therapies for cancer) netted $118.6mm through its initial public offering of 7.5mm shares at $17. Shortly after the company filed in May, it set terms of 6mm shares at $12-14, and then raised the bar just a few weeks later, stating it hoped to sell 7.5mm shares at $15-16.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies